In the present study, patients with mutation at S768I, which was reported to be a potential EGFR-TKI sensitizing NSCLC, had PFS that ranged from 7.8 to 22.5 months, which is consistent with the PFS ranges observed in previous studies [16, 22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.